Risk factors for acute kidney injury in patients with acute myocardial infarction

Figures

• 

  Figure 1. Acute kidney injury incidence and relative mortality among each group by stage. Overall, 26.0% patients developed AKI during the hospitalization, including 11.9% with stage 1, 9.1% with stage 2, and 5.0% with stage 3. Compared with non-AKI group, patients developed AKI have significantly higher in-hospital mortality that raises with stage of AKI (8.2%, 24.5%, and 42.9%, respectively, from stage 1 to 3). AKI: Acute kidney injury.

• 

  Figure 2. Discrimination of risk scores for developing AKI after AMI (n = 1124). Score considered age, hypertension, CKD, Killip classification, extensive anterior myocardial infarction, use of furosemide, and non-use of ACEI/ARB. The weight of each variable was calculated based on their respective multivariate analysis coefficient. ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; AKI: Acute kidney injury; AMI: Acute myocardial infarction; CKD: Chronic kidney disease.

• 

  Figure 3. AKI score calibration. Our AKI risk score considers age (>60 years), hypertension, CKD, Killip class ≥3, extensive anterior myocardial infarction, use of furosemide and non-use of ACEI/ARB, one point for each risk factor. It is an accurate tool to identify patients at high risk of developing AKI. ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; AKI: Acute kidney injury; CKD: Chronic kidney disease.